The U.S.’s largest marijuana legalization organization is launching a search process to find its next executive director on Wednesday, Marijuana Moment has exclusively learned.
The Marijuana Policy Project (MPP), which has played a leading role in efforts to reform cannabis policies on the state and federal levels since 1995, was until late last year led by its founder, Rob Kampia.
But Kampia left the organization as greater attention was paid to past allegations of sexual misconduct against him amidst a national focus on workplace sexual harassment and abuse.
Kampia, for his part, denies that the split had anything to do with his behavior and that he simply wanted to pursue “new business opportunities.”
Now MPP, which has been led on a temporary basis by staffer Matthew Schweich, is looking for Kampia’s permanent replacement.
“Our ideal candidate does not necessarily have a background in marijuana. We are looking for political professionals with experience changing laws, such as a successful campaign manager with a winning track record or a former member of Congress or their staff,” Jeffrey Zucker, chair of MPP’s Board Search Committee, told Marijuana Moment. “But we do want someone with a strong personal commitment to marijuana policy reform, justice and personal liberty.”
The group said in a draft press release that the search will take about three months and will involve targeted outreach to “prominent figures in the fields of politics, social justice and business to ensure the most diverse and inclusive candidate pool possible.”
MPP is especially looking for candidates with political management, fundraising and advocacy experience.
“We are excited to launch this search,” Zucker said. “As a movement, we are close to ending marijuana prohibition in the United States. MPP will continue to play an important role, and we are seeking candidates with experience, expertise and passion for the issue.”
Schweich, the current executive director, will continue leading MPP until a successor is in place and will then focus his attention on the ballot initiative efforts the organization is leading this year, a return to his former role at the organization of leading state campaigns.
“It’s been a privilege to lead this exceptional staff,” he said in the release. “After November, I plan to pursue other opportunities in politics. But first, I want to assist the new executive director during their transition and then help finish what we started in Utah and Michigan. I think both of those ballot initiative campaigns are very important for our movement.”
Meanwhile, Kampia has started a new outfit, the Marijuana Leadership Campaign, which is focused on several of the same state and federal priorities MPP has been working on, leading to some concern that the two groups will compete for resources or duplicate efforts. Kampia has already hired at least one former MPP staffer to join him at the new organization.
See the job posting for the MPP executive director position below:
Job Posting: Executive Director
Lead the marijuana legalization movement.
Marijuana Policy Project (MPP) is the largest organization in the U.S. that’s focused solely on ending marijuana prohibition. The organization is hiring a new Executive Director for the first time since its founding in 1995. MPP works to create a nation where marijuana is legally regulated similarly to alcohol, marijuana education is honest and realistic, and treatment for problem marijuana users is non-coercive and geared toward reducing harm. Marijuana reform is one of the country’s most popular and bipartisan issues, with public support more than doubling over the last 20 years.
MPP has played a leading role in more than half of the current medical marijuana and adult use legalization laws in the country, and the Executive Director should be able to help the organization build on its history of concrete reforms. MPP is lobbying to regulate marijuana like alcohol via several state legislatures: Connecticut, Delaware, Illinois, Maryland, New Hampshire, New Jersey, and Rhode Island. In Michigan, MPP’s coalition is working to legalize and regulate marijuana by voter initiative in 2018. Meanwhile, MPP is also working with patient advocates to advance medical marijuana-related bills in several other states, including Kentucky and South Carolina, while supporting a medical marijuana ballot initiative in Utah. In Congress, MPP has already helped secured protection from federal law enforcement for medical marijuana patients and businesses in the 2018 spending bill and is increasingly lobbying for expanded reforms to banking, research, patient access, and criminal justice.
The Executive Director directly supervises the Chief of Staff and department heads, with responsibility for day-to-day decision-making for the organization. The position develops and implements the organization’s political strategy and goals in conjunction with the staff and Board of Directors. Fundraising is a major part of the job. The position is responsible for the financial stability of the organization and requires a substantial amount of time be dedicated to raising millions of dollars for the organization and campaigns.
Specific responsibilities of the position include, but are not limited to:
- Leading efforts to change laws through political organizing, lobbying, and ballot initiatives.
- Negotiating with a broad range of stakeholders with interests in policy outcomes.
- Raising capital from high net worth individuals, companies, and foundations.
- Creating and executing a fundraising plan with specific outreach goals, timelines, and prospect lists.
- Managing staff and improving individuals’ effectiveness, productivity, and job satisfaction.
- Fostering and maintaining a positive work environment for all staff.
- Communicating with the media to shape public opinion.
- Leading a diverse movement of passionate individuals and organizations with interests in public health and individual liberty.
- Ideal candidate will have a track record for fundraising and a demonstrated ability to run a fast-paced, mission-driven organization of 20 or more employees with a primary focus on changing laws.
- Ten or more years in a professional capacity with increasing levels of responsibility, preferably in politics, public policy, fundraising, or organizational management
- A track record of executive leadership in growing organizations
- Excellence in verbal and written communication and interpersonal skills; ability to motivate teams and to participate in and facilitate group meetings
- Experience in strategic planning and execution; knowledge of contracting, negotiating, and political deal-making
- Ability to adapt and respond to a rapidly changing environment and to encourage and motivate others to do so
- Interest in or personal commitment to marijuana policy reform and individual liberty
This position is required to work out of MPP’s Washington, D.C. headquarters, while also requiring frequent travel and hours commensurate with a C-level position. This position reports to the Board of Directors. Compensation will be commensurate with experience.
For confidential consideration, please send a cover letter, resume, and a list of professional references to [email protected]
Learn more about Marijuana Policy Project, our mission, our accomplishments, and our goals at www.mpp.org.
Former FDA Chief Wants Federal Government To Regulate State Marijuana Markets
Former Food and Drug Administration (FDA) Commissioner Scott Gottlieb said on Monday that the federal government should regulate state marijuana programs.
In his clearest comments on the issue to date, Gottlieb said in a CNBC appearance that the rise in vaping-related lung injuries underscores the need for a federal regulatory scheme that would empower agencies to impose industry standards on aspects of legal cannabis markets such as THC potency and allowable forms of consumption.
Previously, the official had been ambiguous about the extent to which the federal government should get involved, broadly arguing that vaping issues reflect a consequence of conflicting state and federal laws without specifically saying what his preferred policy fix would be. However, in an editorial for The Wall Street Journal published last week, he provided some clarification—hinting that federal drug scheduling laws should be reformed for cannabis—but still left room for interpretation.
But now, he is beginning to lay out specific details of a regulatory agenda.
Gottlieb said during the TV interview that enforcing prohibition is no longer “politically practicable” and that Congress should pass “a federal law that actually can be enforced and allow federal regulatory authorities to impose appropriate supervision.”
While he said he’s not in favor of adult-use legalization and would “like to see the recreational uses shut down entirely,” the reality is that many states have made that decision and so any federal regulatory scheme would have to include “some accommodation of that.”
“I think the time has come that we need to grapple with this at a federal level. We can’t ignore it any more.”
Asked whether states are capable of providing the types of regulations he’s calling for, Gottlieb said no because there’s a patchwork of policies across the country and states “don’t have the capacity to both police what’s being sold in their so-called legal dispensaries as well as shut down the black market.”
“I think you’re going to need federal authorities in there to do that,” he said.
Under the regulatory model Gottlieb is envisioning, FDA and other agencies such as the Drug Enforcement Administration (DEA) “could regulate what’s being sold for the potency, for the manufacturing, for the ingredients, for the claims that are being made.”
“Even if we were to federalize it and allow some form of recreational use, we could limit what can be sold, the potency of what could be sold, the forms in which it can be sold,” he said, adding that he doesn’t think vaping THC products should be allowed.
Federal agencies could impose “tighter controls on the medical claims, holding them to a higher standard and allowing some form of recreational use, probably for products that are lower concentration, that are only delivered in forms that pose less harm than vaping e-liquids,” he said.
“There’s a way to have a compromise where you allow some form of recreational access in the states that want to allow it but something that looks far different than what you have today, something that’s far less permissive than the state laws,” he said. “That’s not a great outcome in my view from a public health standpoint, but what we have now is far worse where you have a federal government not enforcing the law at all—barely enforcing the law—because they know the existing law isn’t practical, and the states not imposing any supervision because they’re incapable of doing it or they don’t want to step in in a vigorous way.”
Photo courtesy of YouTube/CNBC.
Scotland’s Ruling Party Unanimously Backs Drug Decriminalization Measure
Delegates of the Scottish National Party (SNP) unanimously approved a resolution calling for the decriminalization of drug possession and consumption on Sunday.
At a conference in Aberdeen, lawmakers representing Scotland’s largest party and the third largest in the UK Parliament argued that removing criminal penalties for drug offenses and treating addiction as a public health issue would combat an ongoing overdose crisis.
The proposed amendment to the 1971 Misuse of Drugs Act stipulates that the current law is “not fit for purpose in 21st Century Scotland” and would add a provision “to allow for decriminalization of possession and consumption of controlled drugs so that health services are not prevented from giving treatment to those that need it.”
— Alison Thewliss (@alisonthewliss) October 13, 2019
Members of Parliament Tommy Sheppard, Ronnie Cowan and Alison Thewliss of the SNP introduced the measure.
“Our law enforcement agencies are focused on the weak and vulnerable at the bottom of the pyramid, when they should be focused on the organized criminals at the top,” Sheppard said.
He added that if the UK government declines to pursue the reform move, it should “give Scotland the ability to do it instead, because we will take the steps necessary.”
As SNP back decriminalisation to address the drug-death crisis, we spoke to @TommySheppard MP on the need for urgent action to save lives. If Westminster won't act, Scotland must. #SNP19 #skotia pic.twitter.com/zoUWeVYkIZ
— Skotia (@TheSkotia) October 13, 2019
Cowan noted that many people suffering from addiction have experienced some form of trauma and are self-medicating.
“Decriminalization demystifies drugs and places them firmly in the health arena,” he said. “Drug policy is about a mindset. Decriminalization changes the mindset and by changing that you can treat people as human beings and we can start a recovery process.”
As Common Space reported, previous SNP conferences have also seen the passage of progressive drug reform amendments, including one that would establish safe consumption sites to prevent overdoses and help people transition into treatment. Advocates have expressed frustration that the UK Parliament has generally resisted such harm reduction policies.
The Labour Party announced last month that it would launch a Royal Commission dedicated to reviewing the country’s drug laws if elected to the majority.
“The UK government’s cavalier attitude towards Scotland’s drugs emergency is simply appalling,” Thewliss said. “People are dying on our streets and the risk to the general public from discarded needles and transmission of blood borne diseases is very real—yet the Tories at Westminster sit on their hands.”
Glasgow Councillor Mhairi Hunter said at the conference that “challenging the stigma around addiction means challenging the laws that criminalize addiction.”
Over in the U.S., lawmakers remain primarily focused on reforming federal marijuana laws, but talk of broader decriminalization is growing. A survey released earlier this month found that a majority of Americans (55 percent) support the policy change.
Dietary Supplement Industry Pushes Congress To Allow CBD Product Sales
Four trade associations representing the dietary supplement industry signed a letter urging federal lawmakers to take action to provide for the lawful marketing of CBD products while the Food and Drug Administration (FDA) develops its regulations.
The American Herbal Products Association, Consumer Healthcare Products Association, Council for Responsible Nutrition and United Natural Products Alliance said Congress should “pass legislation to clarify that CBD derived from the hemp plant is a lawful dietary ingredient if the dietary supplement containing the CBD meets established product safety and quality criteria.”
To do that, the groups recommended granting a limited waiver that would exempt CBD products from a provision of the Food, Drug and Cosmetic Act that would allow companies to sell CBD as dietary supplements as long as the products are derived from hemp and meet health and safety standards.
“Given the rapidly growing marketplace of products, it is crucial that Congress take quick action to clarify the legal status of hemp-derived CBD dietary supplements,” the letter states. “At the same time, it is equally essential for FDA to have the resources it needs to protect the public from unsafe CBD products.”
A united supplement industry is urging Congress to take swift action on CBD to assure consumer protection and a clear regulatory framework. See what CHPA, @AHPAssociation, @CRN_Supplements, and @unpafrank have to say, here: https://t.co/pUBGSpXFQf
— CHPA (@CHPA) October 10, 2019
“These actions are urgent given the strong consumer interest in CBD, the growth in products and sales, and the need for clarity among consumers, retailers, and manufacturers about the legal status of these products,” the groups said.
Congressional action is needed, they argued, because FDA officials have indicated that the rulemaking process for CBD could take up to five years. They also expressed appreciation for agriculture spending legislation approved by a the Senate committee that would allocate $2 million to FDA to support their efforts to develop cannabidiol regulations.
“We urge Congress to go even further to include substantial new resources to enable effective FDA oversight of this fast-growing category, including funding for efficient and timely review of new dietary ingredient notifications and enforcement of existing laws governing the safety, manufacturing, and labeling of dietary supplements containing CBD,” the letter continues. “We urge that you work with FDA to determine a level of funding adequate to assure effective regulation of the CBD marketplace that does not detract from other agency enforcement priorities.”
“This is the best, most efficient, and most timely way to both set a clear regulatory framework for the marketplace and better assure consumer protection. While we can appreciate the FDA’s deliberative interest in making sure that consumers have access to safe CBD products, we are concerned that continuing to leave the marketplace without clarity and adequate oversight for an extended period of years will both endanger consumers and the bright future of the hemp-derived products they seek. Since it appears FDA is unlikely to provide a timely and effective resolution to this challenge, Congress must act.”
The dietary supplement industry is far from alone in its call for an expedited process to allow CBD products to be marketed.
A bipartisan coalition of senators—and notably, Senate Majority Leader Mitch McConnell (R-KY)—have also urged FDA to clear a path to allow for the lawful marketing of CBD products while the agency continues to develop regulations.
Read the full CBD letter from the dietary supplement industry groups below:
Photo by Kimzy Nanney.